SetPoint Medical Corporation

Quick facts

Phase 3 pipeline

• Conventional Synthetic DMARD · Immunology
  Conventional synthetic DMARDs suppress immune system activity through inhibition of inflammatory pathways to reduce joint inflammation and slow disease progression in rheumatoid arthritis.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• SetPoint Medical Corporation portfolio CI brief
• SetPoint Medical Corporation pipeline updates RSS